AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11301565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7523538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy
Number of subjects: 36
Study 7523538 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic interventions
Number of subjects: 36
Study 2964861 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestogens
Number of subjects: 429
Study 2964861 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 429
Study 28786330 — intervention group
Group type: COMPARATOR
Intervention: Extensive on-site monitoring
Number of subjects: 1618
Study 28786330 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-adapted monitoring
Number of subjects: 1618
Study 26486322 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacker technique for peritoneal closure
Number of subjects: 64
Study 26486322 — intervention group
Group type: COMPARATOR
Intervention: Suture technique for peritoneal closure
Number of subjects: 64
Study 23386054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fidelity training
Number of subjects: 18
Study 23386054 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity training
Number of subjects: 18
Study 23386054 — intervention group
Group type: COMPARATOR
Intervention: Control group (didactic instruction)
Number of subjects: 18
Study 21369739 — intervention group
Group type: EXPERIMENTAL
Intervention: LYMPHA technique (lymphatic-venous anastomoses)
Number of subjects: 46
Study 21369739 — intervention group
Group type: COMPARATOR
Intervention: No preventive surgical approach (control group)
Number of subjects: 46
Study 21369739 — intervention group
Group type: EXPERIMENTAL
Intervention: LYMPHA technique
Number of subjects: 46
Study 18835681 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths-based case management intervention
Number of subjects: 245
Study 18835681 — intervention group
Group type: COMPARATOR
Intervention: Passive referral (control)
Number of subjects: 245
Study 17097217 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine extended release (ER) 4mg QD
Number of subjects: 1698
Study 17097217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1698
Study 15562908 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 15
Study 15562908 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 15
Study 15562908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11676157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical collar therapy
Number of subjects: 38
Study 11676157 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapeutic intervention)
Number of subjects: 38
Study 9089428 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once daily for a maximum of 10 weeks)
Number of subjects: 84
Study 9089428 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (10 mg once daily for a maximum of 10 weeks)
Number of subjects: 84
Study 9089428 — intervention group
Group type: EXPERIMENTAL
Intervention: Metolazone (1 mg once daily for a maximum of 10 weeks)
Number of subjects: 84
Study 8404433 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg three times a day)
Number of subjects: 121
Study 8404433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 3544188 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone/antacid/alginate preparation (Pyrogastrone)
Number of subjects: 59
Study 3544188 — intervention group
Group type: COMPARATOR
Intervention: Antacid/alginate alone (Control)
Number of subjects: 59
Study 30894206 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's bed incline at 45°
Number of subjects: 5866
Study 30894206 — intervention group
Group type: COMPARATOR
Intervention: Mother's bed incline at 15°
Number of subjects: 5866
Study 28853967 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar RF device treatment (4 once-a-week sessions)
Number of subjects: 19
Study 27039080 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin at 20 mg/day
Number of subjects: 16
Study 27039080 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe at 10 mg/day
Number of subjects: 16
Study 27039080 — intervention group
Group type: COMPARATOR
Intervention: Colestimide at 3.62 g/day
Number of subjects: 16
Study 24642620 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin + Decitabine (5-aza-2'-deoxycytidine)
Number of subjects: 30
Study 24642620 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin alone
Number of subjects: 30
Study 22000272 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma education (video scripted at a 4th, 7th, or 10th grade level)
Number of subjects: 127
Study 22000272 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 127
Study 20055764 — intervention group
Group type: EXPERIMENTAL
Intervention: CobraPLA
Number of subjects: 60
Study 20055764 — intervention group
Group type: COMPARATOR
Intervention: LMA
Number of subjects: 60
Study 18793577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin LA(R) under fasted condition
Number of subjects: 28
Study 18793577 — intervention group
Group type: COMPARATOR
Intervention: Medikinet retard under fasted condition
Number of subjects: 28
Study 18793577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin LA(R) under fed condition
Number of subjects: 28
Study 18793577 — intervention group
Group type: COMPARATOR
Intervention: Medikinet retard under fed condition
Number of subjects: 28
Study 16310021 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 31
Study 16310021 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention (Control Group; CG)
Number of subjects: 31
Study 12742488 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 161
Study 12742488 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 161
Study 10233878 — intervention group
Group type: EXPERIMENTAL
Intervention: metronidazole and ciprofloxacin
Number of subjects: 134
Study 10233878 — intervention group
Group type: COMPARATOR
Intervention: ciprofloxacin alone
Number of subjects: 134
Study 10233878 — intervention group
Group type: EXPERIMENTAL
Intervention: combined decontamination medication
Number of subjects: 134
Study 8912751 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide inhalation at 25 ppm
Number of subjects: 7
Study 8373975 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous spinal anesthesia (CS) using CoSPAN catheter
Number of subjects: 60
Study 8373975 — intervention group
Group type: COMPARATOR
Intervention: Single-shot spinal anesthesia (SS)
Number of subjects: 60
Study 8373975 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 3762248 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently high levels of use of services (1974-79)
Number of subjects: 0
Study 3762248 — intervention group
Group type: COMPARATOR
Intervention: Lower levels of use of services (1974-79)
Number of subjects: 0
Study 31608733 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel monotherapy
Number of subjects: 10633
Study 29698250 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (5 mg/kg)
Number of subjects: 197
Study 29698250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 27154174 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg co-administered with vismodegib 150 mg QD for 7 days
Number of subjects: 66
Study 27154174 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg co-administered with vismodegib 150 mg QD for 7 days
Number of subjects: 66
Study 27154174 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg co-administered with vismodegib 150 mg QD for 7 days
Number of subjects: 66
Study 27154174 — intervention group
Group type: COMPARATOR
Intervention: Control arm: Vismodegib 150 mg QD for 7 days
Number of subjects: 66
Study 23402387 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium resonium
Number of subjects: 100
Study 23402387 — intervention group
Group type: COMPARATOR
Intervention: Control group (not on treatment)
Number of subjects: 100
Study 21561544 — intervention group
Group type: EXPERIMENTAL
Intervention: Buttonhole cannulation technique
Number of subjects: 70
Study 21561544 — intervention group
Group type: COMPARATOR
Intervention: Rope ladder rotation technique
Number of subjects: 70
Study 19527323 — intervention group
Group type: EXPERIMENTAL
Intervention: aliskiren/valsartan/HCTZ
Number of subjects: 641
Study 19527323 — intervention group
Group type: EXPERIMENTAL
Intervention: aliskiren/HCTZ
Number of subjects: 641
Study 19527323 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan/HCTZ
Number of subjects: 641
Study 19527323 — intervention group
Group type: COMPARATOR
Intervention: HCTZ alone
Number of subjects: 641
Study 17701949 — intervention group
Group type: EXPERIMENTAL
Intervention: Function-preserving surgery (modified facelift incision, greater auricular nerve preservation, partial parotidectomy, coverage with parotid fascia)
Number of subjects: 101
Study 17701949 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 101
Study 15319760 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation Treatment (SMT)
Number of subjects: 20
Study 15319760 — intervention group
Group type: COMPARATOR
Intervention: Non-Spinal Manipulation Treatment (N-SMT)
Number of subjects: 20
Study 15319760 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 11448383 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication with anterior hiatal repair
Number of subjects: 102
Study 11448383 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication with posterior hiatal repair
Number of subjects: 102
Study 9234829 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 100 mg orally daily for 1 week
Number of subjects: 9
Study 8270925 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (1 g twice daily for six weeks, followed by 1.5 g twice daily for a further six weeks)
Number of subjects: 24
Study 8270925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8270925 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (continued use after the trial)
Number of subjects: 24
Study 3100510 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 63
Study 3100510 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 63
Study 3100510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 27710915 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 28
Study 27710915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 25048345 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiogram (ECG) findings including heart rate, Q waves, and Cornell voltage‐duration product
Number of subjects: 1473
Study 25048345 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ECG variables
Number of subjects: 1473
Study 22203755 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 200 mg twice per day
Number of subjects: 97
Study 22203755 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg twice per day
Number of subjects: 97
Study 22203755 — intervention group
Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD) 50 mg/m² intravenously every 28 days
Number of subjects: 97
Study 20729336 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming loneliness in Studies 1-3
Number of subjects: 420
Study 20729336 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily assessments of positive affect (PA) and relatedness needs satisfaction (RNS) in Study 4
Number of subjects: 420
Study 18611273 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus capecitabine
Number of subjects: 0
Study 18611273 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus a platinum compound
Number of subjects: 0
Study 18611273 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus irinotecan
Number of subjects: 0
Study 18611273 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus 5-fluorouracil
Number of subjects: 0
Study 16013010 — intervention group
Group type: EXPERIMENTAL
Intervention: lipo-prostaglandin E1 (PGE1)
Number of subjects: 42
Study 16013010 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 42
Study 12972964 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesion barrier membrane wrapped around the limbs of the ileostomy, closure at three weeks.
Number of subjects: 0
Study 12972964 — intervention group
Group type: COMPARATOR
Intervention: Control group with no barrier membrane, closure after more than six weeks.
Number of subjects: 0
Study 10378707 — intervention group
Group type: EXPERIMENTAL
Intervention: Samarium-153 particulate hydroxyapatite (Sm-153 PHYP) synovectomy
Number of subjects: 10
Study 8863239 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative, delayed surgery after intensive chemotherapy with or without radiotherapy
Number of subjects: 44
Study 8863239 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional chemotherapy and late exenteration, prostatectomy, or biopsy for patients with relapse or residual disease
Number of subjects: 44
Study 8863239 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross primary excision, local radiotherapy, and vincristine and actinomycin therapy for group IIA tumors
Number of subjects: 44
Study 8863239 — intervention group
Group type: COMPARATOR
Intervention: Control group (IRS‐II)
Number of subjects: 44
Study 8863239 — intervention group
Group type: COMPARATOR
Intervention: Patients with metastatic disease (group IV)
Number of subjects: 44
Study 1651360 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV-specific intravenous immunoglobulin (IVIG) 200 mg/kg on days 8 and 6 before transplant, the day after transplant, weekly for the first month, and then every 2 weeks to complete 10 doses
Number of subjects: 60
Study 1651360 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 60
Study 7075915 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance
Number of subjects: 507
Study 7075915 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 507
Study 7075915 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial test 2-h blood glucose value
Number of subjects: 507
Study 7075915 — intervention group
Group type: EXPERIMENTAL
Intervention: Males and obese subjects
Number of subjects: 507
Study 7075915 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting and 2-h glucose values
Number of subjects: 507
Study 30730425 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration therapy
Number of subjects: 65
Study 30730425 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic physiotherapy
Number of subjects: 65
Study 30730425 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonback pain participants)
Number of subjects: 65
Study 28110153 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficient technique model (1 model)
Number of subjects: 202
Study 28110153 — intervention group
Group type: EXPERIMENTAL
Intervention: Inefficient technique models (4 models)
Number of subjects: 202
Study 28110153 — intervention group
Group type: COMPARATOR
Intervention: Control group (equal number of inefficient and efficient models)
Number of subjects: 202
Study 24655598 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg atomoxetine
Number of subjects: 21
Study 24655598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 24655598 — intervention group
Group type: COMPARATOR
Intervention: No-drug control
Number of subjects: 21
Study 24655598 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 21
Study 24655598 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher structural frontostriatal connectivity
Number of subjects: 21
Study 24507823 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml wine
Number of subjects: 21
Study 24507823 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml wine
Number of subjects: 21
Study 24507823 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 ml wine
Number of subjects: 21
Study 24507823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-off value of 8.84 μg/mg creatinine
Number of subjects: 21
Study 22853848 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/Amlodipine 5 mg (I150/A5)
Number of subjects: 287
Study 22853848 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg (A5)
Number of subjects: 287
Study 22853848 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/Amlodipine 10 mg (I150/A10)
Number of subjects: 287
Study 22853848 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg (A10)
Number of subjects: 287
Study 19282611 — intervention group
Group type: COMPARATOR
Intervention: Patients without cardiac complications
Number of subjects: 4703
Study 19282611 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cardiac complications
Number of subjects: 4703
Study 19282611 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with left ventricular hypertrophy (LVH)
Number of subjects: 4703
Study 19282611 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ischemic heart disease (IHD)
Number of subjects: 4703
Study 17158003 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT) users
Number of subjects: 2181
Study 17158003 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-users of HT)
Number of subjects: 2181
Study 14583744 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (400 mg)
Number of subjects: 10
Study 14583744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12510212 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg transdermal estradiol
Number of subjects: 36
Study 12510212 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg transdermal estradiol
Number of subjects: 36
Study 12510212 — intervention group
Group type: COMPARATOR
Intervention: Transdermal placebo
Number of subjects: 36
Study 10658445 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 alpha-ciclodestrina
Number of subjects: 299
Study 10658445 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no treatment)
Number of subjects: 299
Study 7609170 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 96
Study 7609170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 1965403 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine
Number of subjects: 23
Study 1965403 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 23
Study 1965403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 350397 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with bacillus Calmette‐Guérin
Number of subjects: 79
Study 350397 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with Corynebacterium parvum (C. parvum)
Number of subjects: 79
Study 350397 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (MOCA)
Number of subjects: 79
Study 31443893 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention (MBRP) with at least four sessions
Number of subjects: 72
Study 31443893 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness practice time
Number of subjects: 72
Study 31443893 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness practice time controlling for intervention timing, demographic characteristics, and other factors
Number of subjects: 72
Study 31443893 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness practice time without minimum treatment dose requirement
Number of subjects: 72
Study 27315106 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer victimization (physical, relational, reputational)
Number of subjects: 131
Study 27315106 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational victimization
Number of subjects: 131
Study 27315106 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical victimization
Number of subjects: 131
Study 27315106 — intervention group
Group type: EXPERIMENTAL
Intervention: Victimization type
Number of subjects: 131
Study 25817373 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose adenovirus type-5 vector-based Ebola vaccine
Number of subjects: 120
Study 25817373 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose adenovirus type-5 vector-based Ebola vaccine
Number of subjects: 120
Study 25817373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 23841997 — intervention group
Group type: EXPERIMENTAL
Intervention: Food associated with toys (snacks with toys)
Number of subjects: 600
Study 23841997 — intervention group
Group type: COMPARATOR
Intervention: Food alone (snacks without toys)
Number of subjects: 600
Study 22055504 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day resveratrol (resVida)
Number of subjects: 11
Study 22055504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 19037040 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 800 mcg
Number of subjects: 966
Study 19037040 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal misoprostol 800 mcg
Number of subjects: 966
Study 16925756 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant luteinizing hormone-releasing hormone (LHRH) agonist in Study 1
Number of subjects: 327
Study 16925756 — intervention group
Group type: COMPARATOR
Intervention: LHRH agonist monotherapy or combined androgen blockade in Study 2
Number of subjects: 327
Study 14517191 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil (100 mg oral dose)
Number of subjects: 8
Study 14517191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10740903 — intervention group
Group type: EXPERIMENTAL
Intervention: DHE focused on diet
Number of subjects: 228
Study 10740903 — intervention group
Group type: EXPERIMENTAL
Intervention: DHE focused on oral hygiene instruction (OHI) using fluoride toothpaste
Number of subjects: 228
Study 10740903 — intervention group
Group type: EXPERIMENTAL
Intervention: DHE by a combined diet and OHI message
Number of subjects: 228